Tag Archives: Hartaj Singh

Sunesis Pharma (SNSS) Initiated with a Buy at Oppenheimer

Oppenheimer analyst Hartaj Singh initiated coverage with a Buy rating on Sunesis Pharma (SNSS – Research Report) today and set a price target of $6. The company’s shares opened today at $1.42. Singh noted: “Sunesis (SNSS) reported 1Q19 earnings and

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Clearside Biomedical (NASDAQ: CLSD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Clearside Biomedical (CLSD – Research Report). Sarepta Therapeutics (SRPT) In a report released today, Hartaj Singh from Oppenheimer

United Therapeutics (UTHR) Receives a Buy from Oppenheimer

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a price target of $155. The company’s shares closed yesterday at $99.30, close to its 52-week low of $98.18.

Analysts Are Bullish on These Healthcare Stocks: Alexion Pharmaceuticals (ALXN), Zimmer Biomet Holdings (ZBH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alexion Pharmaceuticals (ALXN – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report) with bullish sentiments. Alexion Pharmaceuticals (ALXN) In a

Cellectis SA (CLLS) Receives a Buy from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Cellectis SA (CLLS – Research Report) today and set a price target of $44. The company’s shares opened today at $19.58. Singh said: “Cellectis (CLLS) announced on 4/2 that its allogeneic

Oppenheimer Thinks SELLAS Life Sciences Group Inc’s Stock is Going to Recover

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS – Research Report), with a price target of $13. The company’s shares opened today at $1.02, close to its 52-week